Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-ESCALaTE HPV
2011-005165-21Phase 3Unknown
- Sponsor
- University of Warwick
- Start
- Jan 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in oropharyngeal squamous cell carcinoma and oropharyngeal cancer comparing Erbitux plus radiotherapy with cisplatin plus radiotherapy (2 arms). Primary endpoint: Total number of severe acute and late toxicity events. Status: unknown.
02
Drugs
cetuximabcisplatin
03
Conditions
oropharyngeal squamous cell carcinomaoropharyngeal cancer
Beyond the preview
Go deeper on 2011-005165-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005165-21.